tradingkey.logo

BUZZ-Lantheus falls on up to $1 billion acquisition

ReutersJan 28, 2025 6:17 PM

Shares of medical diagnostics co Lantheus Holdings LNTH.O fall 7.4% to $91.03

LNTH says it will buy Evergreen Theragnostics to expand its oncology radiopharmaceutical pipeline with multiple experimental cancer treatments

Deal consists of an upfront payment of $250 mln and up to $752.5 mln in milestone payments to Evergreen

JonesTrading analyst Justin Walsh says current weakness in LNTH is due to concerns about the co deploying cash on acquisitions that are expected to add to EPS only ~18 months post-close; he believes this market reaction is "wholly unwarranted"

Deal expected to close in H2 2025

12 of 13 brokerages rate the stock "buy" or higher and 1 "hold"; their median PT is $135 - LSEG

LNTH gained 41.8% in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI